VYNE Therapeutics Inc risk profile
40 Elevated one input has moved against it
Measured 1 September 2026 from VYNE's filed statements. Recomputed nightly.
40 (Elevated), driven by Competitive position at 69, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 48 | Elevated | Volatile | One-year price volatility — 5,534.2% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -45.1 percentage points |
| Cash conversion | 57 | Elevated | Easing | Free-cash-flow margin — -5,811.2% |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA |
| Competitive position | 69 | Stretched | Stable | Operating-margin gap against peers — -5,215.4 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for VYNE Therapeutics Inc